nhia logo

Quick Links
Search NHIA.org



Andrews D. The expanding use of IVIG: Insights into its mechanism of action. 3001;7(7):28-32.

Barrell JM. IVIG: The next distribution battleground? 1999;6(3):35-41.

Barrell JM. Plasma-derived products: No relief in sight. 2001;7(7):34-5.

Barrell JM. Plasma therapies: How new indications, safety measures, and industry consolidation affect supply and demand. 2002;8(4):13-8.

Counce JB. Home IGIV under Medicare: Patients still waiting for meaningful coverage. 2005:11(2):12-20.

Counce J and Kramer N. Case management of the challenging IgG patient: Clinical considerations for the most effective and safe therapy.2009:15(4);S1-S8.

Cohen RJ. Home transfusion therapy: The time has come. 1995;1(6):44-45.

Dalakas M. Update on the Clinical Use and Mechanisms of Action of IVIG in the Treatment of Autoimmune Neurological Disorders. Supplement to: 2010; 16(5).

Hasan A. Reducing Adverse Reactions in Home IVIG Administration—Large Study Shows Clinical Protocols Affect Outcomes. 2012; 18(2):16-20.

Kaplan LK. Lives distrupted: Coping with Bayer Direct. 1999;6(3):42-4.

Kaplan LK. Bayer Responds. 2000;6(4):30.

Kaplan LK. Bayer direct update: Patient advocacy groups speak out. 2000;6(7):12-4.

Kramer N and Krutsinger K. Reducing heparin concentrations in the home care setting: A case study. 2009:15(1);21-4.

Lima HA. Von Willebrand disease: Diagnosis and treatment in the home care setting. 2006. 12(2):S1-S12.

Lima H and Clark A. IgG therapy for the home-based patient: Administration and delivery method considerations. 2012; 18(6):S1-S12.

McKinnon BT. Growth hormone: It's not just for kids. 1999;5(6):32-36.

McKinnon BK. Supply and demand. 1999;5(7):41-43.

Mendelsohn C and Riley P. IGIV fundamentals for home care and alternate site therapy. 2003;9(6):35-8.

Noyes B and Counce J. Medicare IVIG demonstration project—What you need to know. 2014;20(5):42-44.

Orange J. Optimizing immunoglobulin therapy in the treatment of primary immunodeficiency disease. 2011; 17(5):Supp.S1-S12.

Rizk M. Hemophilia and biotechnology: An update. 1999;5(6):23-26.

Siegel J. Guidelines for the safe administration of intravenous immune globulin in the home. 1995;1(10):40-48.

Siegel J. IGIV: Uses in autoimmune diseases. 2004.10(5):S1-S8.

Speidel K. Subcutaneous administration of immunoglobulin replacement therapy in the home care setting. 2006. 12(3):S1-S8.

Werner K. Exciting new IGIV research presented at the 5th international symposium of IGIV. 2004;10(1):33-7.

Zimay D and Erickson K. Pediatric patients with immune disorders: Utilization patterns and clinical outcomes. 1999;5(8):29-33.